

## Advair HFA<sup>®</sup> (fluticasone/salmeterol) – First-time authorized brand alternative

- On March 1, 2023, [Prasco launched](#) an authorized brand alternative of GSK's [Advair HFA \(fluticasone/salmeterol\)](#) inhalation aerosol.
- Advair HFA is approved for the treatment of asthma in adult and adolescent patients aged 12 years and older.
- Fluticasone/salmeterol is also available generically as an [inhalation powder](#) and as brand inhalation powders ([AirDuo<sup>®</sup> Digihaler<sup>®</sup>](#) and [AirDuo RespiClick<sup>®</sup>](#))
  - Fluticasone/salmeterol inhalation powder is approved for the twice-daily treatment of asthma in patients aged 4 years and older.
  - AirDuo Digihaler and AirDuo RespiClick are approved for the treatment of asthma in adult and pediatric patients aged 12 years and older.



At Optum, we help create a healthier world, one insight, one connection, one person at a time. All Optum trademarks and logos are owned by Optum, Inc., in the U.S. and other jurisdictions. All other trademarks are the property of their respective owners. This document contains information that is considered proprietary to Optum Rx and should not be reproduced without the express written consent of Optum Rx. RxNews<sup>®</sup> is published by the Optum Rx Clinical Services Department.